Patents Assigned to Merrimack Pharmaceuticals, Inc.
  • RECOMBINANT HUMAN ALPHA-FETOPROTEIN AS AN IMMUNOSUPPRESSIVE AGENT
    Publication number: 20090053254
    Abstract: Disclosed are methods of inhibiting autoreactive immune cell proliferation in a mammal, involving administering to the mammal a therapeutically effective amount of recombinant human alpha-fetoprotein or an immune cell anti-proliferative fragment or analog thereof.
    Type: Application
    Filed: February 25, 2008
    Publication date: February 26, 2009
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventor: Robert A. Murgita
  • Recombinant human alpha-fetoprotein as an immunosuppressive agent
    Patent number: 7423024
    Abstract: Disclosed are methods of inhibiting autoreactive immune cell proliferation in a mammal, involving administering to the mammal a therapeutically effective amount of recombinant human alpha-fetoprotein or an immune cell anti-proliferative fragment or analog thereof.
    Type: Grant
    Filed: May 4, 2004
    Date of Patent: September 9, 2008
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventor: Robert A. Murgita
  • Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
    Publication number: 20070169211
    Abstract: The invention features non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof.
    Type: Application
    Filed: March 9, 2007
    Publication date: July 19, 2007
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventors: Robert Mulroy, Ian Krane
  • Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
    Patent number: 7208576
    Abstract: The invention features non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof.
    Type: Grant
    Filed: July 22, 2003
    Date of Patent: April 24, 2007
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Robert Mulroy, Ian Krane
  • Cell-based screening methods
    Patent number: 7083938
    Abstract: Cell-based screening methods for determining kinase activity are provided. The methods utilize existing cellular pathways that are regulated by kinases. In one embodiment, various components of a ubiquitin-mediated degradation pathway are modified to create an assay that can be used to screen for a molecule that modulates the activity of a kinase of interest that otherwise does not regulate the degradation pathway. In another embodiment, various components of a protein translocation pathway are modified to screen for a molecule that modulates the activity of a kinase of interest that otherwise does not regulate the translocation pathway.
    Type: Grant
    Filed: February 3, 2004
    Date of Patent: August 1, 2006
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Michael H. Cardone, Michael Yaffe
  • Cell-based screening methods
    Publication number: 20040157272
    Abstract: Cell-based screening methods for determining kinase activity are provided. The methods utilize existing cellular pathways that are regulated by kinases. In one embodiment, various components of a ubiquitin-mediated degradation pathway are modified to create an assay that can be used to screen for a molecule that modulates the activity of a kinase of interest that otherwise does not regulate the degradation pathway. In another embodiment, various components of a protein translocation pathway are modified to screen for a molecule that modulates the activity of a kinase of interest that otherwise does not regulate the translocation pathway.
    Type: Application
    Filed: February 3, 2004
    Publication date: August 12, 2004
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventors: Michael H. Cardone, Michael Yaffe
  • Cell-based screening methods
    Patent number: 6730492
    Abstract: Cell-based screening methods for determining kinase activity are provided. The methods utilize existing cellular pathways that are regulated by kinases. In one embodiment, various components of a ubiquitin-mediated degradation pathway are modified to create an assay that can be used to screen for a molecule that modulates the activity of a kinase of interest that otherwise does not regulate the degradation pathway. In another embodiment, various components of a protein translocation pathway are modified to screen for a molecule that modulates the activity of a kinase of interest that otherwise does not regulate the translocation pathway.
    Type: Grant
    Filed: March 9, 2002
    Date of Patent: May 4, 2004
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Michael H. Cardone, Michael Yaffe